Vasoactive substances in the circulatory dysfunction of cirrhosis

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Scandinavian Journal of Clinical and Laboratory Investigation

• Publication date

  2001-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/00365510152567059PMID 11681531
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides.

  2003cited by this paper
• A prognostic model for predicting survival in cirrhosis with ascites.

  2001cited by this paper
• Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma

  2001cited by this paper
• High arterial compliance in cirrhosis is related to low adrenaline and elevated circulating calcitonin gene related peptide but not to activated vasoconstrictor systems

  2001cited by this paper
• Arterial compliance in patients with cirrhosis: stroke volume-pulse pressure ratio as simplified index.

  2001cited by this paper
• Differential responses of plasma atrial and brain natriuretic peptides to acute alteration in atrial pressure in pigs.

  2000cited by this paper
• Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure.

  2000cited by this paper
• Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.

  2000cited by this paper
• Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

  2000cited by this paper
• Cardiac excitation-contraction coupling in the portal hypertensive rat.

  2000cited by this paper
• Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension.

  2000cited by this paper
• BNP: soon to become a routine measure in the care of patients with heart failure?

  2000cited by this paper
• Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem.

  2000cited by this paper
• Is there a cirrhotic cardiomyopathy

  2000cited by this paper
• Is there a cirrhotic cardiomyopathy?

  2000cited by this paper
• QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes

  2000cited by this paper
• Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase.

  2000cited by this paper
• Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure

  2000cited by this paper
• Cirrhotic cardiomyopathy and liver transplantation

  2000cited by this paper
• Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.

  2000cited by this paper
• Cardiovascular and renal function in normotensive and hypertensive patients with compensated cirrhosis: effects of posture.

  1999cited by this paper
• Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites

  1999cited by this paper
• Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis.

  1999cited by this paper
• An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: development of a test for left ventricular dysfunction.

  1999cited by this paper
• Increased arterial compliance in decompensated cirrhosis.

  1999cited by this paper
• Differential effects of jaundice and cirrhosis on beta-adrenoceptor signaling in three rat models of cirrhotic cardiomyopathy.

  1999cited by this paper
• Elevated circulating cardiac troponin I in patients with cirrhosis

  1999cited by this paper
• Vasopeptidase inhibition: a new concept in blood pressure management.

  1999cited by this paper
• Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt

  1999cited by this paper
• Analysis of impaired exercise capacity in patients with cirrhosis.

  1998cited by this paper
• Pathophysiology of renal fluid retention.

  1998cited by this paper
• Q‐T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors

  1998cited by this paper
• Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems.

  1998cited by this paper
• The sympathetic nervous system in liver disease.

  1998cited by this paper
• Neurohumoral fluid regulation in chronic liver disease.

  1998cited by this paper
• Systemic haemodynamics in cirrhosis and portal hypertension with focus on vasoactive substances and prognosis.

  1998cited by this paper
• Continuous blood pressure monitoring in cirrhosis. Relations to splanchnic and systemic haemodynamics.

  1997cited by this paper
• Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites

  1997cited by this paper
• Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis.

  1997cited by this paper
• Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction.

  1997cited by this paper
• Role of calcitonin gene-related peptide in the vascular system on the development of the hyperdynamic circulation in conscious cirrhotic rats.

  1997cited by this paper
• Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis.

  1997cited by this paper
• Cirrhotic cardiomyopathy: Getting to the heart of the matter

  1996cited by this paper
• Impaired cardiovascular autonomic response to passive tilting in cirrhosis with ascites

  1996cited by this paper
• Urinary excretion of urodilatin in patients with cirrhosis

  1996cited by this paper
• Endothelins in chronic liver disease.

  1996cited by this paper
• Relation of calcitonin gene-related peptide to systemic vasodilatation and central hypovolaemia in cirrhosis.

  1996cited by this paper
• Hyporeactivity of mesenteric resistance arteries in portal hypertensive rats.

  1996cited by this paper
• Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.

  1996cited by this paper
• Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis.

  1995cited by this paper
• Blunted natriuretic response to low‐dose brain natriuretic peptide infusion in nonazotemic cirrhotic patients with ascites and avid sodium retention

  1995cited by this paper
• Altered Control of Vascular Tone by Adenosine Triphosphate- Sensitive Potassium Channels in Rats With Cirrhosis

  1994cited by this paper
• Hepatorenal Disorders: Role of the Renin-Angiotensin-Aldosterone System

  1994cited by this paper
• Peripheral Arterial Vasodilation: Determinant of Functional Spectrum of Cirrhosis

  1994cited by this paper
• Impaired responsiveness to endogenous vasoconstrictors and endothelium-derived vasoactive factors in cirrhosis.

  1994cited by this paper
• Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences

  1994cited by this paper
• Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis.

  1994cited by this paper
• Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats.

  1993cited by this paper
• Calcitonin gene-related peptide in hepatorenal syndrome. A possible mediator of peripheral vasodilation?

  1992cited by this paper
• Estimated central blood volume in cirrhosis: Relationship to sympathetic nervous activity, β‐adrenergic blockade and atrial natriuretic factor

  1992cited by this paper
• Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis.

  1992cited by this paper
• Increased circulating calcitonin gene-related peptide (CGRP) in cirrhosis.

  1991cited by this paper
• Atrial natriuretic factor in cirrhotic patients with tense ascites. Effect of large-volume paracentesis.

  1990cited by this paper
• Vasodilatation associated with hepatocellular disease: relation to functional organ failure.

  1990cited by this paper
• Hepatic-intestinal disposal of endogenous human alpha atrial natriuretic factor99-126 in patients with cirrhosis.

  1990cited by this paper
• Atrial natriuretic factor and renin‐aldosterone in volume regulation of patients with cirrhosis

  1989cited by this paper
• Reduced central blood volume in cirrhosis.

  1989cited by this paper
• Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis.

  1988cited by this paper
• Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites.

  1988cited by this paper
• Systemic circulation.

  1966cited by this paper

• Synbiotic administration improves systemic and vascular alterations in rats with experimental microsurgical extrahepatic cholestasis: role of perivascular mesenteric innervation

  2025cites this paper
• Heyde Syndrome Complicated by Alcoholic Liver Cirrhosis in Which Aortic Valve Stenosis Was Diagnosed due to Gastrointestinal Bleeding

  2025cites this paper
• Keeping an eye on the nutrition: The importance of nutrition management on cardiometabolic risk factors in cirrhotic patients.

  2023cites this paper
• Endothelins and liver cirrhosis

  2022cites this paper
• Serum NT-ProBNP potential marker of cirrhotic cardiomyopathy.

  2022cites this paper
• Mechanisms of kidney dysfunction in the cirrhotic patient: Non-hepatorenal acute-on-chronic kidney damage considerations.

  2020cites this paper
• Disappearance of Angiodysplasia Following Transcatheter Aortic Valve Implantation in a Patient with Heyde's Syndrome: A Case Report and Review of the Literature

  2020cites this paper
• Parenteral Prostacyclin Use in Pulmonary Arterial Hypertension

  2020cites this paper
• Hepatic Encephalopathy-Associated Cerebral Vasculopathy in Acute-on-Chronic Liver Failure: Alterations on Endothelial Factor Release and Influence on Cerebrovascular Function

  2020cites this paper
• Analogies and differences between cirrhotic cardiomyopathy and hepatopulmonary syndrome

  2020cites this paper
• Pulmonary Hypertension: Controversial and Emerging Topics

  2020cites this paper
• A Study of Chronic Liver Disease by Focusing Cardiovascular Changes

  2020cites this paper
• Acute-on-chronic liver disease enhances phenylephrine-induced endothelial nitric oxide release in rat mesenteric resistance arteries through enhanced PKA, PI3K/AKT and cGMP signalling pathways

  2019cites this paper
• Cirrhotic cardiomyopathy

  2019cites this paper
• Diastolic dysfunction in cirrhosis

  2016cites this paper
• Cirrhotic Multiorgan Syndrome

  2015cites this paper
• Cardiac Biomarkers in Cirrhosis and Portal Hypertension: Relation to Circulatory and Cardiac Dysfunction

  2015cites this paper
• Losartan versus Propranolol in Evaluation of Portal Pressure in Patients with Liver Cirrhosis

  2015cites this paper
• Content of Some Endothelium-Dependent Vasoactive Substances of Blood Plasma, Indicators of Renin-Aldosterone System, Natriuretic Hormone in Patients with Decompensated Liver Cirrhosis and their Dependence on the Severity Grade of Portal Hypertension

  2015cites this paper
• Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

  2014cites this paper
• Endothelial Dysfunction in Patients with Chronic HCV Infection

  2014cites this paper
• Management of Cardiopulmonary Complications of Cirrhosis

  2011cites this paper
• Physiopathology of splanchnic vasodilation in portal hypertension.

  2010cites this paper
• ADAMTS13 in arterial thrombosis

  2010cites this paper
• The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients

  2010cites this paper
• Hepatic Physiology and Pathophysiology

  2010cites this paper
• Role of vasoactive substances and cellular effectors in the pathophysiology of cirrhotic portal hypertension: the past, the present and the future--Georges Brohée Lecture.

  2009cites this paper
• Autonomic dysfunction in cirrhosis and portal hypertension

  2008cites this paper
• Increased circulating urotensin II in cirrhosis: potential implications in liver disease.

  2008cites this paper
• Hemodynamic effects of substance P and its receptor antagonist RP67580 in anesthetized rats with carbon tetrachloride-induced cirrhosis

  2008cites this paper
• Potential therapeutic targets in cirrhotic cardiomyopathy.

  2007cites this paper
• Sodium Balance in Cirrhosis

  2007cites this paper
• Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume

  2006cites this paper
• Liver cirrhosis and arterial hypertension.

  2006cites this paper
• Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity

  2006cites this paper
• Changes of nitric oxide and endothelin, thromboxane A2 and prostaglandin in cirrhotic patients undergoing liver transplantation.

  2006cites this paper
• Metabolic Issues in Liver Transplantation

  2006cites this paper
• Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension.

  2006cites this paper
• Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure

  2006cites this paper
• Liver Fibrogenesis: A New Role for the Renin–Angiotensin System

  2005cites this paper
• [Pathogenesis of portal hypertension].

  2005cites this paper
• Portal hypertension: from pathophysiology to clinical practice

  2005cites this paper
• Vasoconstrictor responses are normal but prostanoid‐mediated vasodilatation is enhanced in human cirrhotic mesenteric arteries

  2005cites this paper
• Patogénesis de la hipertensión portal

  2005cites this paper
• Mechanisms of Sodium Retention, Ascites Formation, and Renal Dysfunction in Cirrhosis

  2005cites this paper
• PGE2 alleviates kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats with acute liver damage.

  2005cites this paper
• Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome

  2005cites this paper
• Volume adaptation in chronic liver disease: on the static and dynamic location of water, salt, protein and red cells in cirrhosis

  2004cites this paper
• Hypertension and liver disease

  2004cites this paper
• Pathogenesis and pathophysiology of hepatorenal syndrome – is there scope for prevention?

  2004cites this paper
• Complications of Cirrhosis: Ascites and Spontaneous Bacterial Peritonitis

  2004cites this paper
• Hepatorenal syndrome.

  2003cites this paper
• Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites.

  2003cites this paper
• деяких ендотелійзалежних вазоактивних крові,

  year unknowncites this paper